Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 21 December 2019
Revised: 8 September 2020
Accepted: 12 September 2020
First Online: 30 September 2020
Compliance with ethical standards
:
: N.G. has no disclosures. J.C.T is the Chairman of the DMSB of InflaRx. E.Y. is the site primary investigator for ABROGATE: Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis (Wegener’s) ( Identifier: NCT02108860). She is also the site primary investigator for InflaRx IXPLORE (IFX-1-P2.6): Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) (Clinical Identifier: NCT03712345).
